会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Crystal of a cytochrome-ligand complex and methods of use
    • 细胞色素 - 配体复合物的晶体和使用方法
    • US20090022732A1
    • 2009-01-22
    • US11445018
    • 2006-06-01
    • Eric F. JohnsonJason K. Yano
    • Eric F. JohnsonJason K. Yano
    • A61K39/395C12N9/99A61K31/4436C12N9/02G06T15/00G06G7/58A61P25/34A61K31/444
    • C12N9/0077C07K2299/00Y02A90/26
    • The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the teachings also relate to methods for utilizing a crystal structure of a cytochrome P450 2A6-ligand complex for identifying, designing, selecting, or testing inhibitors of the cytochrome protein. Such inhibitors are useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the cytochrome.
    • 该教导涉及与配体络合的细胞色素蛋白的晶体的三维结构。 公开了四种细胞色素P450 2A6-配体复合物的三维结构。 细胞色素P450 2A6-配体晶体结构,其中配体是抑制剂分子,可用于提供可被整合到药物筛选和药物设计过程中的结构信息。 因此,该教导还涉及利用细胞色素P450 2A6-配体复合物的晶体结构鉴定,设计,选择或测试细胞色素蛋白抑制剂的方法。 这种抑制剂可用作治疗或调节i)疾病的治疗剂; ii)疾病症状; 或iii)由细胞色素介导的其他生理事件的影响。
    • 6. 发明授权
    • Crystal of a cytochrome-ligand complex and methods of use
    • 细胞色素 - 配体复合物的晶体和使用方法
    • US07953557B2
    • 2011-05-31
    • US11445018
    • 2006-06-01
    • Eric F. JohnsonJason K. Yano
    • Eric F. JohnsonJason K. Yano
    • G01N33/48G01N31/00G06G7/58G01N33/53
    • C12N9/0077C07K2299/00Y02A90/26
    • The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the teachings also relate to methods for utilizing a crystal structure of a cytochrome P450 2A6-ligand complex for identifying, designing, selecting, or testing inhibitors of the cytochrome protein. Such inhibitors are useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the cytochrome.
    • 该教导涉及与配体络合的细胞色素蛋白的晶体的三维结构。 公开了四种细胞色素P450 2A6-配体复合物的三维结构。 细胞色素P450 2A6-配体晶体结构,其中配体是抑制剂分子,可用于提供可被整合到药物筛选和药物设计过程中的结构信息。 因此,该教导还涉及用于鉴定,设计,选择或测试细胞色素蛋白抑制剂的细胞色素P450 2A6-配体复合物的晶体结构的方法。 这种抑制剂可用作治疗或调节i)疾病的治疗剂; ii)疾病症状; 或iii)由细胞色素介导的其他生理事件的影响。